# Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT01280786** · PHASE1 · UNKNOWN · sponsor: **Synta Pharmaceuticals Corp.** · enrollment: 36 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Elesclomol Sodium

## Key facts

- **NCT ID:** NCT01280786
- **Lead sponsor:** Synta Pharmaceuticals Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-08
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2014-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01280786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01280786, "Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01280786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*